Hepatitis C: the end of the beginning and possibly the beginning of the end
- PMID: 22351718
- PMCID: PMC3480337
- DOI: 10.7326/0003-4819-156-4-201202210-00014
Hepatitis C: the end of the beginning and possibly the beginning of the end
Conflict of interest statement
Comment on
-
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.Ann Intern Med. 2012 Feb 21;156(4):263-70. doi: 10.7326/0003-4819-156-4-201202210-00378. Epub 2011 Nov 4. Ann Intern Med. 2012. PMID: 22056542 Free PMC article.
-
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.Ann Intern Med. 2012 Feb 21;156(4):279-90. doi: 10.7326/0003-4819-156-4-201202210-00005. Ann Intern Med. 2012. PMID: 22351713 Free PMC article.
References
-
- Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–62. - PubMed
-
- Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989;321:1494–500. - PubMed
-
- Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444–51. - PubMed
-
- Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical